Carol Fabian, MD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Carol Fabian, MD sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Carol Fabian, MD: 14 sponsored US clinical trials, 1 recruiting.
Carol Fabian, MD sponsors 14 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
Carol Fabian, MD ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
14 total, page 1 of 1
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
NCT00291096
Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers
NCT04821375
Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms
NCT04379024
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
NCT03270111
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
NCT02517502
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
NCT02101970
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
NCT01276704
Breast Cancer Risk Biomarkers in Premenopausal Women
NCT01252277
Breast Cancer Risk Biomarkers in Postmenopausal Women
NCT01252290
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
NCT01166763
Study of Breast Cancer Prevention by Letrozole in High Risk Women
NCT00579826
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT00291083
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT00291694
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT00291135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Therapeutic Areas
What is open in the Carol Fabian, MD pipeline
1 recruiting of 14 indexed (7% open); 11 completed (79%).
Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (2 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Carol Fabian, MD: open-pipeline peers nationwide
Peers matched on 14 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Carol Fabian, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
- Minneapolis Veterans Affairs Medical Center · 7% recruiting · 28 trials
Related
What to do with this Carol Fabian, MD page
14 registered trials is a research-attention snapshot, not an endorsement of Carol Fabian, MD or any single study.
- 1 of Carol Fabian, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Carol Fabian, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Carol Fabian, MD pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.